|
|
||||||||
1Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, Oregon; 2Department of Biochemistry and Molecular Genetics, University of Illinois, Chicago, Illinois; and 3Department of Neuroscience, University of Connecticut Health Center, Farmington, Connecticut
Submitted 9 July 2007 ; accepted in final form 9 October 2007
| ABSTRACT |
|---|
|
|
|---|
ATP7B; Wilson disease; basolateral membrane; trafficking
-amidating monooxygenase, Cu,Zn-superoxide dismutase, and others. However, excess copper can be toxic, and maintenance of copper balance in cells is critical. Two copper-transporting P-type ATPases (Cu-ATPases), ATP7A and ATP7B, play a central role in this process. Cu-ATPases have dual functions in the delivery of copper to cuproenzymes in the trans-Golgi network (TGN) and in exporting excess copper from the cell. Inactivation of either ATP7A or ATP7B in humans results in severe metabolic disorders, Menkes disease and Wilson disease, respectively. Menkes disease is characterized by defective copper transport from the enterocytes into the circulation and is associated with severe copper deficiency in several tissues, particularly in the brain. In Wilson disease, copper export from the liver into the bile is disrupted, resulting in marked copper overload in the liver. Although phenotypic manifestations of the two diseases are very different, both Menkes disease and Wilson disease result in copper accumulation in kidneys (3, 22). This observation suggests that both ATP7A and ATP7B are necessary for normal renal copper balance. Currently, the specific contribution of each Cu-ATPase to renal copper metabolism is poorly understood. Renal copper content is among the highest in the body (15) and is tightly regulated. In dietary deficiency or in a situation when intestinal copper absorption is greatly diminished due to genetic inactivation of the copper uptake protein CTR1, the kidney copper content appears less affected compared with other tissues (23, 28). This is also the case in Menkes disease, where defective copper export from the intestine results in copper deficiency in most other tissues, yet copper levels in the kidney rise above that of healthy individuals (22). In patients with Wilson disease patients and in mouse models, copper is markedly elevated in the liver at a young age, whereas renal copper rises more slowly (1, 3, 4), suggesting a more precise control of renal copper content. This tighter control could be, at least partially, due to the presence of two (rather than one) Cu-ATPases, and it may involve fine-tuned cross talk between ATP7A and ATP7B. Currently, the information on the localization and function of ATP7A and ATP7B in kidney is very limited.
Recent studies of the expression and localization of ATP7A and ATP7B in the kidney have yielded inconsistent results. In situ hybridization of ATP7A mRNA in the mouse kidney showed strong staining in proximal tubules (19), in contrast to another study in which the glomerulus showed the strongest staining and proximal tubules were stained weakly (17). In immunochemistry experiments using control and brindled mice (an animal model of Menkes disease), ATP7A was detected in the proximal and distal tubules but not in the glomerulus (6). In a study of transgenic mice overexpressing human ATP7A, two transgenic strains showed different patterns of ATP7A expression in kidney, which included distal tubules, the loops of Henle, outer medulla, and the podocytes of the glomerulus, but no expression in proximal tubule (9). No staining of the transgene product was seen in the proximal tubules. ATP7B distribution was investigated only in one study, and both mRNA and protein were found in the glomerulus and inner and outer medulla (17).
The discrepancies in the reported localization of Cu-ATPases could be due to varying animal strains and ages as well as the detection of mRNA compared with protein. To date, no developmental studies of Cu-ATPase in the kidney have been reported. Similarly, the effects of altered copper levels on endogenous Cu-ATPases in the kidney remain unknown. It was previously reported that recombinant ATP7A, when expressed in Madin-Darby canine kidney (MDCK) cells, undergoes trafficking from the intracellular vesicles to the basolateral membrane in response to high extracellular copper (5). Whether changes in serum copper have any effect on endogenous ATP7A in vivo has not been investigated. To begin addressing these important issues, we performed high-resolution immunohistochemical mapping of endogenous ATP7A in the tubular epithelial cells of mouse kidney. Our studies revealed a widespread distribution of ATP7A in kidney and demonstrated that the intracellular localization of endogenous ATP7A is age-dependent and can be modulated in vivo by changes in serum copper or by inactivation of another copper-transporting ATPase, ATP7B. Altogether, our results support the role of ATP7A in copper export across the basolateral membrane for reabsorption into the blood; in addition, they provide a direct demonstration of a cross talk between the two renal copper-transporting ATPases.
| METHODS |
|---|
|
|
|---|
Antibodies and peptides.
Primary antibody
-C-Mnkp CT77 was previously described (29). This antibody is directed against a short, COOH-terminal peptide of mouse ATP7A, D1475–L1492. The secondary goat anti-rabbit IgG antibody conjugated to Cy3 was obtained from Molecular Probes (Eugene, OR). To determine specificity of immunostaining by CT77, two recombinant peptides were generated, expressed in Escherichia coli, purified, and used for preabsorption experiments. The "specific" competing peptide C-Mnkp corresponded to Y1410–L1501 of human ATP7A, and the "nonspecific" competing peptide C-Wndp corresponded to the Y1376–L1465 fragment of ATP7B. Both peptides, which share
55% sequence identity, are 12.5 kDa in size with a 6-His tag.
Fluorescent immunohistochemistry. Mice were euthanized by CO2 inhalation and subjected to transcardial perfusion with a 0.9% NaCl solution followed by a solution of 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS), pH 7.4. Kidneys were quickly removed and fixed in 4% PFA for 24 h at 4°C and then soaked in 20% sucrose overnight at 4°C. The kidneys were embedded in Tissue-Tek O.C.T. compound (Sakura FineTechnical, Tokyo, Japan) at –20°C and then sectioned into 20-µm sagittal slices using a Leitz Cryostat (Wetzlar, Germany). The slices were placed onto gelatin/poly-L-lysine-coated slides and stored at –80°C. Kidney sections were taken from three animals for each category and each age group.
Slides were warmed to room temperature, and kidney sections were rehydrated with PBS for 5 min. Sections were blocked with 5% goat serum, 1% BSA, and 0.2% Triton X-100, in PBS, for 1 h at room temperature (RT). After a brief rinse in PBS, slides were incubated in the primary antibody (CT77 at 1:2,000) in dilution buffer (DB: 0.25% BSA and 0.2% Triton X-100, in PBS) for 2 h at RT. Slides were washed three times for 10 min in PBS and then incubated in the secondary antibody (Alexa Fluor 555 goat anti-rabbit IgG diluted 1:3,000) in DB for 1 h in the dark. After three more 10-min washes in PBS, slides were mounted using Vectashield with 4',6-diamidine-2-phenylindole (Vector Labs, Burlingame, CA) and analyzed using a Zeiss LSM5 scanning confocal microscope (Carl Zeiss, Jena, Germany). To determine signal specificity, the CT77 antibody was incubated with 150 µg of C-Mnkp or C-Wndp for 1 h at 4°C before being diluted in DB, and the mixture was then added to slides. Experiments were repeated at least three times, and a minimum of five images per sample were analyzed to determine the most representative staining patterns.
Cell lines. All cultured cell lines were from American Type Culture Collection (Manassas, VA). MDCK and opossum kidney (OK) cells were maintained in Eagle's minimum essential medium (GIBCO, Grand Island, NY) supplemented with 10% fetal bovine serum (GIBCO), 2 mM L-glutamine (GIBCO), 1.5 g/l sodium bicarbonate, 0.1 mM nonessential amino acids, 1.0 mM sodium pyruvate (Invitrogen, Carlsbad, CA), and 100 U/ml penicillin and streptomycin (Invitrogen).
Copper measurements.
Blood was collected from animals during transcardial perfusion. After the right atrium was cut open, blood was allowed to drain into the thoracic cavity and was collected before the 0.9% saline solution was injected into the left ventricle. The blood was allowed to clot and was subsequently centrifuged twice for 5 min at 8,000 rpm. Serum was decanted and frozen at –80°C. Freshly removed kidneys were bisected sagittally, and cortex and medulla were dissected; renal pelvis was discarded. Digestion of tissue was done using the wet ashing protocol described by Parker et al. (26). Briefly, the samples were heated under reflux in 0.5 ml of concentrated HNO3 (
69.5%; Mallinckrodt Baker, Phillipsburg, NJ) for 45 min, cooled to room temperature, transferred to a graduated cylinder, and diluted with water to yield 10 ml (acid concentration
3.5%).
Atomic absorption measurements were carried out using an AA6650 spectrometer equipped with a graphite furnace and ASC6100 autosampler (Shimadzu, Kyoto, Japan). Samples (both serum and digested tissue samples) were diluted with 2% HNO3 to be in the linear absorption range of the calibration curve [1–10 parts per billion (ppb, or ng/l)]. Each sample (20 µl) was injected two to three times depending on the standard deviation of measurements. The copper concentration was derived by comparing the absorption of the sample with that of a standard curve. Standard deviations were calculated to reflect the variance in the measurements. All values are expressed as means ± SD.
| RESULTS |
|---|
|
|
|---|
|
To further verify the specificity of immunostaining, the anti-ATP7A antibody (CT77) was preincubated with the purified recombinant peptide corresponding to the COOH-terminal fragment of ATP7A (C-Mnkp), which contains the epitope for CT77. For a negative control, we used the recombinant COOH-terminal fragment of ATP7B (C-Wndp), which is 55% identical to the C-Mnkp peptide but differs in the epitope region. When blocked with the C-Mnkp peptide, CT77 antibody no longer produced the staining and only a faint haze remained (Fig. 1D, middle). Blocking with the C-Wndp peptide had no significant effect on the immunofluorescent pattern (Fig. 1D, right), confirming the specificity of ATP7A staining seen with CT77 (Fig. 1D, left).
Intracellular localization of ATP7A is age dependent. The variable intensity of staining along the nephron that we observed in our experiments and differing patterns previously reported for mice of different ages (10 and 60 days) prompted us to examine whether the expression and distribution of ATP7A in kidney could change during kidney maturation. In general, the localization of a Cu-ATPase at the basolateral membrane of epithelial cells (a membrane facing the blood) would be consistent with its role in exporting copper back into circulation (reabsorption). By contrast, the presence at the apical membrane (the interior portion of renal tubules) would suggest a role for Cu-ATPase in transporting copper into the lumen of tubules for removal of excess copper with urine. Intracellular staining would be consistent with the role in the biosynthesis of cuproproteins and/or copper storage function.
To determine whether the distribution (and presumably function) of ATP7A changes as kidney mature, we compared the ATP7A staining in kidneys of 2-, 8-, and 20-wk-old mice. These experiments yielded very interesting results (Fig. 2). The overall intensity and distribution of ATP7A in renal tissue appeared similar in animals at these three ages, suggesting a lack of considerable fluctuation in protein abundance during kidney maturation or with age. At the same time, there was a very clear age-dependent difference in the intracellular localization of ATP7A (Fig. 2). In 2-wk-old kidneys, epithelial cells of many cortical tubules showed staining of ATP7A close to or at the basolateral membrane (Fig. 2, left). In the cortex of 8-wk-old kidneys, some tubules showed basolateral staining in their epithelial cells, while in other tubules the localization of ATP7A was mostly vesicular and perinuclear (Fig. 2, middle). The intracellular perinuclear staining became predominant in 20-wk-old animals (Fig. 2, right). The ATP7A staining in the medulla was mostly perinuclear in both young and adult mice (data not shown).
|
Analysis of tissue (5–7 animals per age group) demonstrated that copper levels in either cortex or medulla of 2-wk-old kidney were not elevated compared with those of older animals (Fig. 3A). In the cortex of 2-wk-old kidney, where the localization of ATP7A at the basolateral membrane was the most apparent, the copper concentration in tissue was similar or even slightly lower compared with that in the 8-wk-old samples (3.72 ± 1.17 vs. 4.59 ± 0.34 ppb), but clearly not higher (see also Fig. 3A). This result ruled out the high steady-state levels of copper in tissue as a reason for ATP7A relocalization toward basolateral membrane. Alternatively, it seemed possible that in younger animals, serum copper levels could be higher, and hence more copper could be entering epithelial cells from the serum. In this scenario, an increase in copper levels would induce the relocalization of ATP7A toward basolateral membrane, stimulate copper export, and consequently decrease copper levels in tissue. To examine whether more copper is present in the serum of younger mice, we compared copper concentrations in the serum of 2- and 8-wk-old animals, using 6–9 mice for each age group. These measurements did not lend sufficiently strong support to the hypothesis. Although serum copper was on average higher in the 2-wk-old mice compared with the 8-wk-old animals (161.02 ± 37.29 and 144.61 ± 25.59 ppb, respectively), this difference was not statistically significant due to large animal-to-animal variation of values (Fig. 3B).
|
In control kidneys, as expected, all mice showed ATP7A staining in the intracellular compartments; however, in many tubules of copper-injected animals, a significant portion of ATP7A was also detected at or near the basolateral membrane (Fig. 4). For a more quantitative comparison, five images from each sample were used to quantify the number of tubules with significant basolateral staining of ATP7A compared with the total number of stained tubules. In saline-injected samples, only 13% (±6.5%) of tubules displayed basolateral ATP7A staining, whereas in samples from copper-injected animals, approximately one-half of the tubules 46% (±7.3%) showed predominant staining in the proximity of the basolateral membrane. Thus endogenous ATP7A traffics in vivo in response to changing copper levels, and elevation of copper in serum can serve as a signal for such relocalization.
|
|
The intracellular localization of ATP7A is altered in Atp7b–/– kidney. The coexpression of two Cu-ATPases in renal cells indicated that both transporters were likely to play a role in balancing renal copper. Our results suggested that ATP7A was likely to export excess copper across the basolateral membrane (see above). To better understand the contribution of ATP7B to renal copper homeostasis, we examined the effects of ATP7B inactivation on renal copper concentration and ATP7A localization using Atp7b–/– mice. We hypothesized that in the absence of functional ATP7B, more copper will stay in the cytosol of epithelial cells, thus increasing, to a certain degree, the intracellular copper concentration. In response, ATP7A may traffic toward basolateral membrane to facilitate copper export and compensate for the lack of ATP7B activity. The results of our experiments (Fig. 6) are consistent with this scenario.
|
Our experiments using wild-type animals indicated that the trafficking of ATP7A in kidney could be induced by changes in serum copper concentration (see above). Consequently, it was important to verify that the changes in the intracellular localization of ATP7A in Atp7b–/– mice were not due to elevated copper in a serum, which could be an indirect effect of ATP7B inactivation in other tissues. Copper measurements showed that serum copper concentration of the 8-wk-old Atp7b–/– animals was not elevated compared with the 8-wk-old wild-type animals (116.31 ± 57.68 ppb in the knockouts compared with 144.61 ± 25.59 ppb in the wild type, Fig. 3B).
ATP7A partially compensates for the lack of ATP7B function.
In the liver, where ATP7B is the major copper exporter (ATP7A is not expressed in hepatocytes), inactivation of ATP7B is associated with a large (
20-fold higher than the norm) increase in copper content (4, 8). Consequently, it was interesting to determine the levels of copper in the Atp7b–/– kidney, where ATP7A relocalized to the basolateral membrane (see above), presumably to export copper. Atomic absorption measurements of copper in kidneys of 8-wk-old control and Atp7b–/– mice showed no significant copper accumulation at this stage (Fig. 3A). Concentration of copper in cortex and medulla of Atp7b–/– mice was comparable to copper concentration in the corresponding regions of the wild-type mice (4.95 ± 1.08 vs. 4.59 ± 0.34 ppb for cortex and 4.71 ± 0.83 vs. 4.57 ± 0.32 ppb for medulla) (Fig. 3).
The lack of significant copper increase in Atp7b–/– kidneys suggested that ATP7A compensates for the absence of transport activity of ATP7B. However, this compensation is incomplete, and the kidney metabolism is altered. This was evident from the accumulation of bright fluorescent material, which was present endogenously and was unrelated to immunostaining (Fig. 6B, top). No such fluorescence was seen in control kidney (Fig. 6B, bottom). This material concentrated in a fairly narrow zone of the outer medulla of Atp7b–/– kidney and showed yellow-orange fluorescence under UV light (360 nm). Similar yellow-orange fluorescence was previously observed in kidneys of Lon-Evans cinnamon (LEC) rats (which also lack functional ATP7B) and was ascribed to the presence of a copper-metallothionein (Cu-MT) complex (25). In Atp7b–/– kidneys, however, the accumulated material also fluoresced under longer wavelengths (up to 630 nm), suggesting that the increased autofluorescence was due to regional accumulation of more than one metabolite.
| DISCUSSION |
|---|
|
|
|---|
The wider distribution of ATP7A observed in our studies compared with previous reports can be explained by the utilization of a more sensitive antibody and fluorescent detection, which further increases sensitivity compared with previously used color detection. Our data agree with the studies reporting high ATP7A expression in cortical tubules and not in the glomerulus (6, 9, 19). It should be noted, however, that the tubules adjacent to glomeruli are brightly stained, and therefore, at low magnification, the characteristic morphology of the Bowman's capsule and proximal convoluted tubule surrounding the glomerulus is easily discernable.
Our experiments using high-magnification confocal imaging yielded additional information on intracellular localization of ATP7A in different tubules. Within the medulla, ATP7A is found almost entirely in the perinuclear region of epithelial cells, in contrast to the perinuclear, vesicular, and basolateral staining seen in the cortex. Previous studies in polarized and nonpolarized cells demonstrated that trafficking of ATP7A from the perinuclear region toward the plasma membrane occurs when extracellular copper is elevated and results in copper export from the cell (5, 13, 24, 27). Therefore, the predominance of ATP7A staining in the perinuclear region of cells in the medulla compared with the cortex may reflect a gradient of extracellular copper along the nephron and/or a low amount of copper export and reabsorption in the loops of Henle compared with that in proximal and distal tubules of the cortex. Similarly, the cortical tubules that exhibit the most basolateral staining are probably those involved in the majority of copper transport from the kidney back into circulation.
Because of the lack of convenient marker antibodies that could be used for colocalization with CT77 (non-rabbit and non-mouse), the precise identity of regions with different localization patterns of ATP7A remains to be determined. However, copper injection experiments illustrate that renal ATP7A relocalizes in vivo and that ATP7A traffics toward the basolateral membrane not only in tubules, where some basolateral staining was already present, but also in other tubules (as evidenced by a significant, up to 50%, increase in the number of tubules with basolateral location of ATP7A). This observation suggests that copper reabsorption into the circulation via ATP7A can occur, when necessary, along a large portion of the nephron; however, under normal conditions, only a very small fraction of the renal tubules is involved in this process.
The experiments in mice of different age demonstrated, for the first time, that the relocalization of ATP7A in vivo also occurs in response to physiological changes that accompany kidney maturation. The large difference in localization of renal ATP7A in 2-wk-old mice (mostly basolateral) and 20-wk-old mice (mostly perinuclear) is unrelated to cortical copper concentration, which is clearly not elevated in younger mice. Our analysis of serum, however, cannot exclude the possibility that younger animals have slightly higher copper levels in the serum or that these levels fluctuate more than in adult animals. In cultured cells, the increase of copper in the medium as low as 1 µM triggers relocalization of endogenous ATP7A toward the plasma membrane (24), whereas in animals, the large animal-to-animal variation prevents detection of such small changes. The robust trafficking of renal ATP7A in response to acute copper elevation is consistent with the role of serum copper in altering the ATP7A localization. In addition to regulation by changing copper levels, hormonal regulation of ATP7A trafficking was recently described in placental and mammary cells (7, 10). No information is currently available about hormonal control of renal copper homeostasis; therefore, one cannot exclude the possibility that the localization and function of ATP7A in the kidney can also be modulated by factors other than fluctuations in serum copper levels. If ATP7A localization indeed parallels the copper-export activity of ATP7A, then one would predict that young mice have higher levels of copper reabsorption in the cortex and that this transport decreases with age.
In LEC rats, which lack functional ATP7B, excess copper bound to metallothionein (Cu-MT) was observed in the outer medulla and, to a lesser extent, in the in proximal convoluted tubule cells (25). In contrast, in macular mice, which have impaired ATP7A, Cu-MT was seen only in the cells of proximal convoluted tubules (30, 32). These early results point to an important involvement of both ATP7A and ATP7B in copper homeostasis in proximal tubules. The marked change in the intracellular localization of ATP7A that we observed in the cortical tubules of Atp7b–/– mice complements the earlier data and strongly supports this conclusion.
Altogether, the data are consistent with a role for ATP7A in the transport of copper across the basolateral membrane and, hence, in copper reabsorption into the blood. The copper injection experiments indicate that it is renal ATP7A that responds to short-term serum copper fluctuations. We suggest that ATP7A, which shows faster kinetics properties than ATP7B (2), works as a housekeeping copper transporter and provides fast response to elevated copper by trafficking to renal basolateral membrane. Inactivation of ATP7A would prevent export of copper from the tubules resulting in copper accumulation.
The role of renal ATP7B appears to be to fine-tune the intracellular copper concentration, likely by transporting copper into intracellular vesicles. Our data suggest that inactivation of ATP7B may cause local changes in copper concentrations that trigger trafficking of ATP7A toward plasma membrane for the restoration of copper balance. Thus the export of excess copper by ATP7A is one of the likely reasons for a very slow copper accumulation by Atp7b–/– kidneys. Although this explanation is consistent with a greatly increased basolateral localization of ATP7A in Atp7b–/– mice, more complex systemic effects of ATP7B inactivation on kidney cannot be excluded. Development of tissue-specific knockouts would greatly facilitate understanding of tissue-specific functions for Cu-ATPases.
The absence of functional ATP7B in Atp7b–/– mice also leads to the appearance of fluorescent deposits in the outer medulla. Interestingly, the observed pattern of increased autofluorescence in the narrow region of outer medulla is similar to the pattern of Cu-MT fluorescence seen in LEC rats (25) (see above). However, the fluorescence characteristics differ in Atp7b–/– mice and LEC rats. The fluorescent material in the Atp7b–/– mice is excited at UV (360 nm) and longer wavelengths (up to 630 nm), suggesting that, in our case, it represents a mixture of substances, possibly including lipofuscin. Lipofuscin is a fluorescent pigment that has a broad absorption and excitation spectrum, and it progressively accumulates as a result of autophagocytosis of modified molecules within secondary lysosomes. Lipofuscin particles containing accumulated copper were previously observed in the liver of Wilson disease patients (18). In Atp7b–/– mice, similar accumulation of lipofuscin-like material occurs in a specific kidney region, suggesting that this is the region where the function of ATP7B is particularly important.
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
* R. Linz and N. L. Barnes contributed equally to this work. ![]()
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. Kim, H.-Y. Son, S. M. Bailey, and J. Lee Deletion of hepatic Ctr1 reveals its function in copper acquisition and compensatory mechanisms for copper homeostasis Am J Physiol Gastrointest Liver Physiol, February 1, 2009; 296(2): G356 - G364. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |